This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Dynavax Technologies Corporation Of Class Action Lawsuit And Deadline Of August 19, 2013 To Seek Lead Plaintiff Position

Stocks in this article: DVAX

NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation ("Dynavax" or the "Company") (Nasdaq: DVAX) stock between April 26, 2012 and June 10, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/dynavax-technologies-dvax/ .   

The complaint alleges that defendants violated federal securities laws by issuing materially false and misleading statements concerning the viability of their drug HEPLISAV. In particular, it is alleged that during the Class Period Dynavax concealed from the public that: (1) the clinical trial for HEPLISAV was flawed because it was not representative of the US population and lacked information regarding concomitant use of HEPLISAV with other vaccines; (2) Dynavax failed to provide the FDA with sufficient data concerning its manufacturing processes and controls for HEPLISAV.

On June 10, 2013, Dynavax disclosed that the FDA required additional data regarding the safety of HEPLISAV before it could further review the drug for potential approval.

If you suffered a loss in Dynavax you have until August 19, 2013 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/dynavax-technologies-dvax/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq.30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500Toll Free:  (877) 363-5972Fax: (866) 367-6510 www.zlk.com

SOURCE Levi & Korsinsky, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs